| Oct 21 |
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
|
| Oct 10 |
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
|
| Sep 23 |
Skye stock rallies 22% following weight-loss drug update
|
| Sep 23 |
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
|
| Sep 20 |
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
|
| Sep 4 |
Skye: Moving Weight Loss Drugs To The Next Level
|
| Sep 3 |
Skye Bioscience appoints Puneet Arora as chief medical officer
|
| Sep 3 |
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
|
| Aug 26 |
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
|
| Aug 23 |
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
